Bispecific antibodies designed to recognize two different epitopes or antigens aim to address the host immune activity towards tumor cells by binding both tumor-enriched antigens (i.e., CEA, CEACAM, EpCAM, HER2, or CD276 antigen) and immune cells (mainly T cells via the CD3 receptor) and are being explored under this rationale in different types of solid tumors [89]. The gene discussed is EPCAM; the disease is neoplasm.